Korean J Gastroenterol.  2017 Nov;70(5):232-238. 10.4166/kjg.2017.70.5.232.

Trend in the Eradication Rates of Helicobacter pylori Infection Over the Last 10 Years in West Gyeonggi-do, Korea: A Single Center Experience

• Park JS
• Park JE
• Oh BS
• Yoon BW
• Kim HK
• Lee JW
• Kim NH
• Cho WS
• Woo YS
• Jahng J
• Kim YS

• KMID: 2398869
• DOI: http://doi.org/10.4166/kjg.2017.70.5.232

Abstract

BACKGROUND/AIMS
The eradication rate of Helicobacter pylori (H. pylori) has been decreasing recently in Korea due to antibiotics resistance. The aim of this study was to investigate the trend of eradication rate and clinical factors affecting the eradication rate of H. pylori in the last 10 years in west Gyeonggi-do, Korea.
METHODS
The trends of eradication rate of H. pylori, gender, age, concomitant mediations, and clinical factors were retrospectively evaluated in patients with H. pylori infection between 2006 and 2015 (n=2,485).
RESULTS
The overall H. pylori eradication rate for the standard triple therapy was 82.5%. The annual eradication rates from 2006 to 2015 were 90%, 77.9%, 75.8%, 83.2%, 85.6%, 90.1%, 81.3%, 81.1%, 78.7%, and 78.8%, respectively, showing a significant decrement during the last five years (p < 0.001). Higher eradication rate was observed in males than in females (p < 0.001). Esomeprazole showed a higher eradication rate compared with pantoprazole between 2006 and 2010 (p < 0.022). Age and the use of probiotics and mucosal protective agents played no significant role in the H. pylori eradication rate. The overall eradication rate for bismuth-based quadruple therapy was 94.4%.
CONCLUSIONS
The eradication rate of H. pylori over the last 10 years for first-line therapy ranged from 75.8 to 90.1%; the eradication rate for triple therapy has declined. However, the eradication rate for quadruple therapy has remained unchanged over the last 10 years.

Keyword

Helicobacter pylori; Disease eradication; Korea

MeSH Terms

Anti-Bacterial Agents
Disease Eradication
Esomeprazole
Female
Gyeonggi-do*
Helicobacter pylori*
Helicobacter*
Humans
Korea*
Male
Probiotics
Protective Agents
Retrospective Studies
Anti-Bacterial Agents
Esomeprazole
Protective Agents

Figure

• 

  Fig. 1 Annual Helicobacter pylori eradication rates from 2006 to 2015 according to regimen and treatment duration.

• 

  Fig. 2 Annual proportion of treatment duration with first-line therapy.

Reference

1. Choi KD. Current trends of Helicobacter pylori eradication in Korea. Korean J Helicobacter Up Gastrointest Res. 2015; 15:147–154.

2. Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. Korean J Gastroenterol. 2013; 62:3–26.

3. Shin WG, Lee SW, Baik GH, et al. Eradication rates of Helicobacter pylori in Korea over the past 10 years and correlation of the amount of antibiotics use: nationwide survey. Helicobacter. 2016; 21:266–278.

4. Hwang TJ, Kim N, Kim HB, et al. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol. 2010; 44:536–543.

5. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol. 2002; 97:2744–2749.

6. Song MJ, Park DI, Park JH, et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter. 2010; 15:206–213.

7. Lü M, Yu S, Deng J, et al. Efficacy of probiotic supplementation therapy for Helicobacter pylori eradication: a meta-analysis of randomized controlled trials. PLoS One. 2016; 11:e0163743.

8. Kashimura H, Suzuki K, Hassan M, et al. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment Pharmacol Ther. 1999; 13:483–487.

9. Nishizawa T, Nishizawa Y, Yahagi N, Kanai T, Takahashi M, Suzuki H. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014; 29:Suppl 4. 20–24.

10. Lu C, Sang J, He H, et al. Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis. Sci Rep. 2016; 6:23522.

11. Choi YS, Cheon JH, Lee JY, et al. The trend of eradication rates of first-line triple therapy for Helicobacter pylori infection: single center experience for recent eight years. Korean J Gastroenterol. 2006; 48:156–161.

12. Kim BG, Kim JS, Kim B, Ji JS, Choi H, Park SM. Annual eradication rates of Helicobacter pylori infection over 9 years in Incheon. Korean J Helicobacter Up Gastrointest Res. 2015; 15:103–107.

13. Jung YS, Lee SH, Park CS, et al. Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years. Korean J Gastroenterol. 2014; 63:82–89.

14. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004; 53:1374–1384.

15. Lee JW, Kim N, Kim JM, et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013; 18:206–214.

16. Song JG, Lee SW, Park JY, et al. Trend in the eradication rates of Helicobacter pylori infection in the last 11 years. Korean J Med. 2009; 76:303–310.

17. Kim BJ, Kim HS, Song HJ, et al. Online registry for nationwide database of current trend of Helicobacter pylori eradication in Korea: interim analysis. J Korean Med Sci. 2016; 31:1246–1253.

18. Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013; (12):CD008337.

19. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017; 66:6–30.

20. Kim BG, Lee DH, Ye BD, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter. 2007; 12:31–35.

21. Vallve M, Vergara M, Gisbert JP, Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther. 2002; 16:1149–1156.

22. Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008; 28:868–877.

23. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016; 65:1439–1446.

24. Kim MN, Kim N, Lee SH, et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter. 2008; 13:261–268.

25. Kim JW. The effects of probiotics on the treatment of Helicobacter pylori eradication. Korean J Helicobacter Up Gastrointest Res. 2016; 16:129–133.

26. Szajewska H, Horvath A, Kołodziej M. Systematic review with meta-analysis: saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2015; 41:1237–1245.

27. Hayashi S, Sugiyama T, Amano K, et al. Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother. 1998; 42:1895–1899.

28. Haruma K, Ito M. Review article: clinical significance of mucosal- protective agents: acid, inflammation, carcinogenesis and rebamipide. Aliment Pharmacol Ther. 2003; 18:Suppl 1. 153–159.